纳武利尤单抗联合化疗治疗胃癌假性进展1例并文献复习

国际肿瘤学杂志››2025,Vol. 52››Issue (6): 395-397.doi:10.3760/cma.j.cn371439-20241221-00068

纳武利尤单抗联合化疗治疗胃癌假性进展1例并文献复习

王旻¹, 温馨格², 魏毓正², 孙诚诚², 周婷婷¹()

¹bobapp1中国有限公司附属省立医院专科护理门诊，济南 250021
²bobapp1中国有限公司（山东省医学科学院）研究生部（研究生教育中心），济南 250117

收稿日期:2024-12-21修回日期:2025-02-10出版日期:2025-06-08发布日期:2025-06-26
通讯作者:周婷婷 E-mail:847925147@qq.com

Received:2024-12-21Revised:2025-02-10Online:2025-06-08Published:2025-06-26

摘要/Abstract

摘要：

近年来免疫检查点抑制剂（ICI）在临床的广泛应用极大改善了肿瘤患者的预后，同时也出现了假性进展和超进展等特殊疗效模式。如何正确判断假性进展从而合理评估ICI的疗效，为临床治疗决策带来巨大挑战。现报道1例晚期胃癌患者在纳武利尤单抗联合化疗中出现假性进展并最终肿瘤明显缩小的诊疗经过，并就相关文献进行复习，以提高对该类疾病的认识。

王旻, 温馨格, 魏毓正, 孙诚诚, 周婷婷. 纳武利尤单抗联合化疗治疗胃癌假性进展1例并文献复习[J]. 国际肿瘤学杂志, 2025, 52(6): 395-397.

图/表1

参考文献14

[1]	Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J].Lancet,2021,398(10294): 27-40. DOI:10.1016/S0140-6736(21)00797-2. pmid:34102137
[2]	Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics[J].Lancet Oncol,2017,18(3): e143-e152. DOI:10.1016/S1470-2045(17)30074-8.
[3]	Queirolo P, Spagnolo F. Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: a systematic review[J].Cancer Treat Rev,2017,59: 71-78. DOI:10.1016/j.ctrv.2017.07.002. pmid:28756306
[4]	Park HJ, Kim KW, Pyo J, et al. Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors:asystematic review and meta-analysis[J].Radiology,2020,297(1): 87-96. DOI:10.1148/radiol.2020200443.
[5]	Billan S, Kaidar-Person O, Gil Z. Treatment after progression in the era of immunotherapy[J].Lancet Oncol,2020,21(10): e463-e476. DOI:10.1016/S1470-2045(20)30328-4.
[6]	Michalarea V, Fontana E, Garces AI, et al. Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: case series and short literature review[J].Curr Probl Cancer,2019,43(5): 487-494. DOI:10.1016/j.currproblcancer. 2019.01.008.
[7]	Martin-Romano P, Castanon E, Ammari S, et al. Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types[J].Cancer Med,2020,9(8): 2643-2652. DOI:10.1002/cam4. 2797.
[8]	Nishino M, Giobbie-Hurder A, Manos MP, et al. Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab:identifying markers for clinical outcome and treatment decisions[J].Clin Cancer Res,2017,23(16): 4671-4679. DOI:10.1158/1078-0432.CCR-17-0114. pmid:28592629
[9]	Fujimoto D, Yoshioka H, Kataoka Y, et al. Pseudoprogression in previously treated patients with non-small cell lung cancer who received nivolumab monotherapy[J].J Thorac Oncol,2019,14(3): 468-474. DOI:10.1016/j.jtho.2018.10.167. pmid:30468872
[10]	Di Giacomo AM, Danielli R, Guidoboni M, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases[J].Cancer Immunol Immunother,2009,58(8): 1297-1306. DOI:10.1007/s00262-008-0642-y. pmid:19139884
[11]	Tanizaki J, Hayashi H, Kimura M, et al. Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression[J].Lung Cancer,2016,102: 44-48. DOI:10.1016/j.lungcan.2016.10.014. pmid:27987588
[12]	Frelaut M, du Rusquec P, de Moura A, et al. Pseudoprogression and hyperprogression as new forms of response to immunotherapy[J].Bio Drugs,2020,34(4): 463-476. DOI:10.1007/s40259-020-00425-y.
[13]	Tabei T, Tsuura Y, Kobayashi K. Pseudoprogression: a case of metastatic renal clear cell carcinoma treated with nivolumab[J].Pathol Int,2018,68(11): 627-629. DOI:10.1111/pin.12714. pmid:30151940
[14]	Jia W, Gao Q, Han A, et al. The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy[J].Cancer Biol Med,2019,16(4): 655-670. DOI:10. 20892/j.issn.2095-3941.2019.0144. pmid:31908886

[1]	王青, 陈婷, 高静东, 彭春雷.天蟾胶囊治疗化疗所致周围神经病理性疼痛的临床观察[J]. 国际肿瘤学杂志, 2025, 52(5): 288-294.
[2]	孙玉娇, 于美丽, 马文静, 孙龙美, 朱兆峰, 郑媛媛.可切除局部晚期食管鳞状细胞癌新辅助免疫治疗的临床应用进展[J]. 国际肿瘤学杂志, 2025, 52(5): 309-314.
[3]	刘海燕, 张超.基于CT影像加权组学评分构建非小细胞肺癌的免疫治疗疗效预测模型[J]. 国际肿瘤学杂志, 2025, 52(4): 202-208.
[4]	刘前怡, 董洪敏, 王文玲, 王刚, 陈望花.放疗联合化疗和免疫治疗对HER2阴性局部晚期或晚期胃癌的临床疗效和安全性[J]. 国际肿瘤学杂志, 2025, 52(4): 209-216.
[5]	文英美, 夏锦雄, 王园园, 姚颐.放疗对抗肿瘤免疫的影响：从基础到临床[J]. 国际肿瘤学杂志, 2025, 52(4): 231-236.
[6]	王智颖, 盛立军.外周血标志物在非小细胞肺癌免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(3): 180-185.
[7]	王熙博, 田宝文, 陈士巧.Breg细胞在肿瘤免疫逃逸中的机制及相关治疗靶点[J]. 国际肿瘤学杂志, 2025, 52(2): 107-112.
[8]	陈茹雁, 付振明.晚期肾细胞癌的免疫治疗现状与进展[J]. 国际肿瘤学杂志, 2025, 52(2): 124-128.
[9]	.胃癌筛查与早诊早治方案（2024年版）[J]. 国际肿瘤学杂志, 2025, 52(2): 65-66.
[10]	姬海涛, 王延峰, 刘永成, 郝楠.基于生物信息学分析DHCR7在胃癌中的表达及临床意义[J]. 国际肿瘤学杂志, 2025, 52(2): 94-100.
[11]	谭荣坚, 欧雯婷, 翟嘉伟, 全祯豪, 孙利君, 周才进.RRM2通过调控CDK1对胃癌细胞恶性生物学行为及有氧糖酵解的影响[J]. 国际肿瘤学杂志, 2025, 52(1): 23-30.
[12]	黄镇, 晏菲, 马燕凌, 孙建海.食管癌靶向及免疫治疗研究进展[J]. 国际肿瘤学杂志, 2025, 52(1): 53-59.
[13]	伍杨, 李甜, 张润兵, 史婷婷, 高春, 郑晓凤, 张久聪.胃癌及食管胃结合部癌免疫及靶向治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(9): 595-600.
[14]	刘文会, 殷平, 戚洁.血清G-17、sB7-H3、DKK1检测对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(8): 498-503.
[15]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.

纳武利尤单抗联合化疗治疗胃癌假性进展1例并文献复习

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表1

参考文献14

相关文章15

编辑推荐

Metrics

本文评价